About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

April 30, 2024 For Release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 473-5712 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum • Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. • Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; ...

Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's disease in the U.S. and EU; resubmission of lebrikizumab for atopic dermatitis in the U.S.; and initiation of lepodisiran in a Phase 3 study for atherosclerotic cardiovascular disease. Q1 2024 EPS increased 66% to $2.48 on a reported basis and increased 59% to $2.58 on a ...

There's no stopping this high-flying biotech.The pharmaceutical business is a tricky one. Developing novel therapies costs hundreds of thousands of dollars, sometimes more. Many never make it to the market despite substantial sums invested by drugmakers. Many of those that do earn approval end up falling short of sales expectations. However, occasionally, some drug therapies pay for the money invested in their development several times over.Analysts think that's the kind Eli Lilly (LLY 1.19%) has in tirzepa ...

These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.Nvidia has been an amazing stock to own over the past few years, generating incredible returns for investors. But the risk is that expectations may be too high for the stock, especially with respect to artificial intelligence (AI). And that means the stock could be vulnerable to a sell-off if reality doesn't align with the sky-high expectations investors and consumers have created for AI.The fut ...

Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound have become staples for treating diabetes and obesity.Eli Lilly (LLY 1.19%) is the developer of Mounjaro and Zepbound, two popular medications used to treat those conditions. The main compound in each drug is called tirzepatide, and Lilly h ...

Analyst Estimates for Q1 2024Q4 2023Q1 2023Revenue$8.79 billion$9.35 billion$6.96 billionDiluted EPS$2.39$2.42$1.49Net Income$2.15 billion$2.19 billion$1.34 billion Key Metric: New Products Revenue The weight-loss drugs were the biggest driver of Eli Lilly's revenue in the fourth quarter, with Mounjaro accounting for $2.21 billion, with Zepbound generating just $175.8 million in its first quarter on the market. Combined, the two weight-loss drugs made up just over a quarter of Eli Lilly's total fourth qu ...

Core Viewpoint - Eli Lilly is expected to report strong Q1 results driven by its diabetes and weight-loss drugs, with projected sales of $8.9 billion and adjusted earnings per share of $2.46, reflecting significant growth from previous periods [1][5]. Stock Performance - Eli Lilly's stock has increased by 330% from $170 in January 2021 to around $730, significantly outperforming the S&P 500, which rose about 35% during the same period [2]. - The stock delivered returns of 64% in 2021, 32% in 2022, and 59% in 2023, while the S&P 500 had returns of 27% in 2021, -19% in 2022, and 24% in 2023 [2]. Revenue and Earnings Growth - In the previous quarter, Eli Lilly reported revenue of $9.4 billion, a 28% year-over-year increase, driven by market share gains for drugs like Mounjaro, Verzenio, and Jardiance [4]. - Mounjaro sales surged 8x to $2.2 billion, while Verzenio sales increased by 42% year-over-year to $1.1 billion [4]. - Adjusted earnings grew by 19% to $2.49 per share, despite a charge of $0.62 per share related to acquired in-process research and development [4]. Future Projections - For the latest quarter, Mounjaro sales are expected to rise over 3x year-over-year to around $2 billion, with Verzenio sales projected to exceed $1 billion [5]. - Eli Lilly anticipates 2024 sales between $40.4 billion and $41.6 billion, with adjusted earnings per share ranging from $12.20 to $12.70, marking a significant increase from 2023's sales of $34.1 billion and adjusted EPS of $6.32 [5]. Market Position and Valuation - Eli Lilly's valuation is heavily reliant on future pipeline potential rather than current earnings, with analysts' average price estimates at $825, over 10% above the current market price of around $730 [3].

In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $2.53 per share, reflecting an increase of 56.2% compared to the same period last year. Revenues are forecasted to be $8.81 billion, representing a year-over-year increase of 26.6%.The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates duri ...

Eli Lilly and Company (LLY) will report first-quarter 2024 results on Apr 30, before market open.The Zacks Consensus Estimate for this drug giant’s first-quarter revenues is pegged at $8.81 billion, while the same for earnings per share is $2.53 per share, both indicating significant increases from the year-ago quarter.In the first quarter, top-line growth is expected to have been driven by strong demand for Lilly’s new tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. The Za ...